Abstract:
Thioureas/Thiosemicarbazones are small molecules studied extensively in drug design due to their wide range of biological activities. Selenium is shown to be involved in various metabolic processes in the human body, and low Se levels are observed in the plasma regions of AD patients. Based on this fact, we have synthesized Thiosemicarbazone ligands and Acyl-selenourea ligands as inhibitors of A𝛽 aggregation. We hypothesize that the seleno-derivatives will exhibit higher activity than their thio-derivatives. We have also conducted in-silico studies to gain a broader view of the interactions which take place. The docking studies show that there is no considerable difference in the binding abilities and the interactions of the synthesized
Acyl-selenourea ligands compared to their corresponding acyl-thiourea counterparts.
